Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
@article{Matthys2014ReviewOG, title={Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?}, author={Frederik Matthys and Tine L M de Backer and Guy G. De Backer and Robert Vander Stichele}, journal={European Journal of Preventive Cardiology}, year={2014}, volume={21}, pages={354 - 365} }
Aims There are numerous national and international guidelines on the use of aspirin for the primary prevention of cardiovascular disease. Given the uncertainties about aspirin in primary prevention, our aim was to compare the recommendations and the reported evidence in guidelines for the treatment with aspirin of subjects free of cardiovascular disease with or without diabetes. Methods and Results Guidelines were retrieved through Medline and other electronic databases and through a web-based…
20 Citations
Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
- MedicineScientific reports
- 2021
The widespread use of aspirin, especially among older adults, and substantial concomitant use of medications adding to bleeding risk warrant increased focus on discontinuation of inappropriate aspirin use.
Aspirin Use and Mortality in Two Contemporary US Cohorts
- MedicineEpidemiology
- 2018
Results from these 2 large population-based US cohorts confirm the utility of daily aspirin use for secondary prevention of cardiovascular mortality; however, the data suggest that caution should be exercised in more frequent use, particularly among individuals without a history of cardiovascular disease.
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of HypertensionWorking Group on Hypertension and Cardiovascular Risk in Low Resource Settings HYPERTENSION IN A GLOBAL PERSPECTIVE
- Biology
- 2014
Current evidence for cardiovascular risk assessment in population studies in low-income and middle-income countries, their limitations, possible improvements, and future interests in screening programs are summarized and highlights of unmet needs are presented.
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings
- MedicineJournal of hypertension
- 2014
Current evidence for cardiovascular risk assessment in population studies in low-income and middle-income countries, their limitations, possible improvements, and future interests in screening programs are summarized and highlights of unmet needs are presented.
Frequency of Aspirin Misuse Among Hypertensive Patients in Babylon Province
- MedicineMedico-Legal Update
- 2020
Aspirin use requires coordinated interaction between patient and physician with encouraging the importance patient education about aspirin use, side effects and CVD risk and proper evaluation of patients risk factors and stratification using simplified charts accessible in health centers.
Pooled RCTs: Low-dose ASA reduced CV events in persons <70 kg; higher-dose ASA was effective at higher body weights
- MedicineAnnals of Internal Medicine
- 2018
In primary prevention, low- dose aspirin vs control reduced cardiovascular events in patients weighing <70 kg but not those weighing 70 kg, and higher-dose aspirin was effective at higher body weights.
Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study
- Medicine, Political ScienceBMJ Open
- 2021
Widespread adoption of these new guidelines could be an important strategy to reduce the incidence of bowel cancer, but this will require more active implementation strategies focused on primary care and the wider community.
Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study
- MedicinePloS one
- 2015
Background Presence of non-obstructive coronary artery disease (CAD) is associated with increased prescription of cardiovascular preventive medications including aspirin. However, the association…
A Geripill for Successful Aging
- MedicineJournal of the American Geriatrics Society
- 2013
My reasons for shunning the aspirin, beta-blocker, and hydrochlorothiazide of the original “polypill” are the side effects and low evidence of benefit of aspirin in primary prevention and the good tolerability and benefits of newer antihypertensive drug combinations.
Reduction of intracerebral hemorrhage in hemodialysis patients after reducing aspirin use: A quality-assurance observational study
- Medicine, BiologyPloS one
- 2017
Minimizing aspirin use in hemodialysis patients with severe hypertension reduced intracerebral bleeding without a significant difference in cardiovascular mortality.
References
SHOWING 1-10 OF 89 REFERENCES
Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale
- MedicineAnnals of Internal Medicine
- 2002
The USPSTF concluded that the balance of benefits and harms is most favorable in patients at high risk for coronary heart disease (those with a 5-year risk 3%) but is also influenced by patient preferences, and some persons at lower risk may consider the potential benefits of aspirin to outweigh the potential harms.
Aspirin for primary prevention: yes or no?
- MedicineJournal of primary health care
- 2010
Benefits of aspirin monotherapy outweigh the harms for both men and women aged up to 80 years with calculated five-year CVD risk >15% in primary prevention, and modelling by risk category and age group suggests that current guidelines are justified in recommending aspirin for primary prevention of CVD.
Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
- MedicineThe American journal of medicine
- 2004
Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis
- MedicineExpert opinion on pharmacotherapy
- 2010
The use of aspirin cannot be routinely recommended for primary prevention of cardiovascular events in diabetes, as existing trials were limited by small patient numbers and low cardiovascular event rates.
Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.
- MedicineThe American journal of cardiology
- 2011
An update on aspirin in the primary prevention of cardiovascular disease.
- MedicineArchives of internal medicine
- 2003
The current totality of evidence provides strong support for the initial finding that aspirin reduces the risk of a first MI, and the benefits of long-term aspirin therapy are likely to outweigh any risks.
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
- MedicineDiabetes research and clinical practice
- 2010
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice
- MedicineThe Lancet
- 2001
Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.
- MedicineBritish journal of clinical pharmacology
- 2001
Aspirin was associated with UGIC even when used at low doses or in buffered or enteric-coated formulations, and the latter findings may be partially explained by channeling of susceptible patients to these formulations.
Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force
- MedicineAnnals of Internal Medicine
- 2002